[go: up one dir, main page]

JO3112B1 - تركيبة دوائية سريعة التحلل - Google Patents

تركيبة دوائية سريعة التحلل

Info

Publication number
JO3112B1
JO3112B1 JOP/2011/0100A JOP20110100A JO3112B1 JO 3112 B1 JO3112 B1 JO 3112B1 JO P20110100 A JOP20110100 A JO P20110100A JO 3112 B1 JO3112 B1 JO 3112B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical composition
fast dissolving
dissolving pharmaceutical
matrix network
open matrix
Prior art date
Application number
JOP/2011/0100A
Other languages
English (en)
Inventor
Gunjikar Tejas
Ahuja Varinder
Wannerberger Kristin
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3112B1 publication Critical patent/JO3112B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/50Polysaccharides, gums
    • A23V2250/502Gums
    • A23V2250/5062Inulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير تركيبة صيدلانية تشتمل على شبكة مصفوفة مفتوحة تحمل المكون النشط صيدلانياً، حيث تشتمل شبكة المصفوفة المفتوحة على إنولين.
JOP/2011/0100A 2010-03-29 2011-03-22 تركيبة دوائية سريعة التحلل JO3112B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN742DE2010 2010-03-29

Publications (1)

Publication Number Publication Date
JO3112B1 true JO3112B1 (ar) 2017-09-20

Family

ID=54241475

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0100A JO3112B1 (ar) 2010-03-29 2011-03-22 تركيبة دوائية سريعة التحلل

Country Status (23)

Country Link
US (2) US10086078B2 (ar)
EP (1) EP2552403B1 (ar)
JP (1) JP5907945B2 (ar)
KR (1) KR101725173B1 (ar)
CN (1) CN102821755A (ar)
AR (1) AR080736A1 (ar)
AU (1) AU2011234636B2 (ar)
BR (1) BR112012024428A2 (ar)
CA (1) CA2793405A1 (ar)
DK (1) DK2552403T3 (ar)
ES (1) ES2553568T3 (ar)
HU (1) HUE026213T2 (ar)
IL (1) IL222086A (ar)
JO (1) JO3112B1 (ar)
MX (1) MX2012011204A (ar)
NZ (1) NZ602441A (ar)
PL (1) PL2552403T3 (ar)
PT (1) PT2552403E (ar)
RU (1) RU2566270C2 (ar)
SA (1) SA111320317B1 (ar)
TW (1) TWI513477B (ar)
WO (1) WO2011120903A2 (ar)
ZA (1) ZA201207176B (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2493457T3 (ar) 2009-10-30 2018-01-06
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
NZ620897A (en) * 2011-09-16 2016-07-29 Ferring Bv A fast dissolving pharmaceutical composition
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CN106456535B (zh) * 2014-04-25 2020-07-03 R.P.谢勒技术有限公司 稳定的孟鲁司特溶液
JP7042275B2 (ja) 2017-01-11 2022-03-25 フェリング・ベー・フェー 速崩壊性医薬組成物
CN111904936B (zh) * 2020-08-28 2022-07-19 开封康诺药业有限公司 一种法莫替丁冻干粉针剂
MX2023003432A (es) 2020-09-29 2023-08-04 Millicent Pharma Ltd Formulaciones orodispersables.
EP4243602A4 (en) 2020-11-16 2024-11-13 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA251629A (en) 1925-07-14 T. Hanna William Coal cutting knife
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
JPS5446841A (en) 1977-08-16 1979-04-13 Wellcome Found Drug substituted hapten substance and production thereof
CN1053808C (zh) 1993-04-24 2000-06-28 章修纲 尼非地平控释剂型
EP0879600A1 (en) 1997-05-20 1998-11-25 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Fructan containing composition for the prevention and treatment of colon cancer
EP0958825A1 (en) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
AU1453600A (en) 1998-11-04 2000-05-22 Mcneil-Ppc, Inc. Solid oral dosage forms containing alginic acid and famotidine
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.
EP1064938A1 (en) 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2001012161A1 (en) * 1999-08-17 2001-02-22 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
WO2002005855A1 (fr) 2000-07-13 2002-01-24 Daiichi Pharmaceutical Co., Ltd. Compositions pharmaceutiques contenant des composes dds
IT1319664B1 (it) * 2000-11-17 2003-10-23 Pharma Biotech Ltd Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali.
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
MXPA04009673A (es) * 2002-04-03 2005-01-11 Solvay Pharm Bv Formulacion de cannabinoide natural estabilizado.
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE60307082D1 (de) 2002-05-07 2006-09-07 Ferring Bv In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
CZ200482A3 (cs) * 2002-05-27 2004-05-12 Advanceáholdingsálimited Potravinové doplňky z vinných výpalků a způsob jejich výroby
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
CA2516291C (en) 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
DK1514553T3 (da) 2003-09-05 2008-06-23 Myung-Jun Chung Mælkesyrebakteriepulver, der er dobbeltbelagt under anvendelse af protein og polysaccharid og fremgangsmåde til fremstilling af samme samt dosisform af dette
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
US20060088593A1 (en) 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
CN100339081C (zh) * 2004-11-10 2007-09-26 范敏华 一种氯雷他定口腔崩解片剂的制备方法
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
BRPI0519212A2 (pt) * 2004-12-23 2009-01-06 Mcneil Ppc Inc composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial
US20070042023A1 (en) 2005-08-22 2007-02-22 National Starch And Chemical Investment Holding Corporation Dissolvable film
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2007143676A2 (en) 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
KR20090109131A (ko) 2007-03-27 2009-10-19 더 프록터 앤드 갬블 캄파니 생균제를 투여하기 위한 방법 및 키트
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
KR100930427B1 (ko) 2008-01-25 2009-12-08 정명준 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
PL2318511T3 (pl) * 2008-08-28 2018-01-31 Chr Hansen As Kompozycja bakteryjna
ES2643087T3 (es) 2010-03-29 2017-11-21 Ferring B.V. Composición farmacéutica de disolución rápida
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
NZ620897A (en) 2011-09-16 2016-07-29 Ferring Bv A fast dissolving pharmaceutical composition
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release

Also Published As

Publication number Publication date
US20130123180A1 (en) 2013-05-16
CN102821755A (zh) 2012-12-12
AU2011234636B2 (en) 2015-01-15
RU2566270C2 (ru) 2015-10-20
EP2552403B1 (en) 2015-09-09
PL2552403T3 (pl) 2016-01-29
ES2553568T3 (es) 2015-12-10
NZ602441A (en) 2014-01-31
EP2552403A2 (en) 2013-02-06
ZA201207176B (en) 2013-05-29
DK2552403T3 (en) 2015-10-05
KR101725173B1 (ko) 2017-04-10
JP2013523676A (ja) 2013-06-17
SA111320317B1 (ar) 2015-05-11
TWI513477B (zh) 2015-12-21
TW201138830A (en) 2011-11-16
PT2552403E (pt) 2015-10-30
WO2011120903A2 (en) 2011-10-06
AU2011234636A1 (en) 2012-10-11
US20180369392A1 (en) 2018-12-27
BR112012024428A2 (pt) 2016-05-31
CA2793405A1 (en) 2011-10-06
MX2012011204A (es) 2012-11-23
RU2012141141A (ru) 2014-05-10
US10512695B2 (en) 2019-12-24
HUE026213T2 (en) 2016-05-30
KR20130008588A (ko) 2013-01-22
US10086078B2 (en) 2018-10-02
AR080736A1 (es) 2012-05-02
HK1181649A1 (en) 2013-11-15
WO2011120903A3 (en) 2012-05-03
JP5907945B2 (ja) 2016-04-26
IL222086A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
MX350447B (es) Composicion farmaceutica de disolucion rapida.
SA112330855B1 (ar) تركيبة صيدلانية سريعة الذوبان
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
EP3216448B8 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
EP2657231A4 (en) SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING AND USING SAME
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
IN2015DN03984A (ar)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
TW200942524A (en) Novel aminomethyl benzene derivatives
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
TW200942530A (en) Pyridine compounds
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
MX339306B (es) Agente anti-fungico.
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
WO2011156045A3 (en) Tablet formulation of ezatiostat
HK1197378A (en) A fast dissolving pharmaceutical composition
WO2010104485A3 (en) Valsartan formulations
UA72107U (en) Dosage form of licopen
侯雁林 Woman: A Constructed Being